Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tania Jain

Showing results (61-70 of 118) with videos related to

Pageof 12
Sort By:
Bone Marrow Transplantation|May 26, 2018
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosisTania Jain, Katie L Kunze, M'hamed Temkit, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 14, 2018
Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective StudyTania Jain, Heidi E Kosiorek, Shu T Kung, et al.
Leukemia & Lymphoma|April 5, 2022
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapyTheodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek, et al.
Leukemia & Lymphoma|February 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantationJohn Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur, et al.
Haematologica|June 11, 2026
Evolution to complex karyotype disease in mono-allelic <i>TP53</i>-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort studyPriyanka Fernandes, Sergiu Pasca, Tania Jain, et al.
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Leukemia|October 19, 2021
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter studySiddharth Kunte, Lisa Rybicki, Auro Viswabandya, et al.
Frontiers in Immunology|June 25, 2024
Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myelomaDoris K Hansen, Binod Dhakal, Mehdi Hamadani, et al.
Leukemia Research|September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbiditiesJ Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.
Haematologica|December 15, 2022
CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidineTheodoros Karantanos, Patric Teodorescu, Marios Arvanitis, et al.
Pageof 12

Showing results (61-70 of 118) with videos related to

Sort By:
Pageof 12
Bone Marrow Transplantation|May 26, 2018
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosisTania Jain, Katie L Kunze, M'hamed Temkit, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 14, 2018
Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective StudyTania Jain, Heidi E Kosiorek, Shu T Kung, et al.
Leukemia & Lymphoma|April 5, 2022
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapyTheodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek, et al.
Leukemia & Lymphoma|February 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantationJohn Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur, et al.
Haematologica|June 11, 2026
Evolution to complex karyotype disease in mono-allelic <i>TP53</i>-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort studyPriyanka Fernandes, Sergiu Pasca, Tania Jain, et al.
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Leukemia|October 19, 2021
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter studySiddharth Kunte, Lisa Rybicki, Auro Viswabandya, et al.
Frontiers in Immunology|June 25, 2024
Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myelomaDoris K Hansen, Binod Dhakal, Mehdi Hamadani, et al.
Leukemia Research|September 17, 2025
Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbiditiesJ Preston Claiborne, Daniel Li, Hua-Ling Tsai, et al.
Haematologica|December 15, 2022
CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidineTheodoros Karantanos, Patric Teodorescu, Marios Arvanitis, et al.
Pageof 12